Market Cap (In USD)
995.41 Million
Revenue (In USD)
27.96 Million
Net Income (In USD)
-160.27 Million
Avg. Volume
1.24 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 9.41-19.09
- PE
- -
- EPS
- -
- Beta Value
- 1.632
- ISIN
- US05337M1045
- CUSIP
- 05337M104
- CIK
- 1012477
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Gregory J. Divis Jr.
- Employee Count
- -
- Website
- https://www.avadel.com
- Ipo Date
- 1996-06-07
- Details
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
More Stocks
-
7936ASICS Corporation
7936
-
6728ULVAC, Inc.
6728
-
NAKSH
-
6674GS Yuasa Corporation
6674
-
MNKDMannKind Corporation
MNKD
-
ACCR
-
TERASOFTTera Software Limited
TERASOFT
-
VGIDV Group, Inc.
VGID